Clinical Trial Update: Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Roluperidone (MIN-101) for negative symptoms of schizophrenia has completed and results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Negative Symptoms of Schizophrenia
• Schizophrenia

Drugs mentioned

• Roluperidone (roluperidone)

Snippet

Sponsor: Minerva Neurosciences | Conditions: Negative Symptoms of Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2023-04-28